These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 3042215)
1. Metabolic effects of continuous subcutaneous insulin infusion: evidence that a rise and fall of portal vein insulin concentration with each major meal facilitates post-absorptive glycemic control. Rodger NW; Behme MT; Dupre J; Chamberlain MJ Clin Invest Med; 1988 Jun; 11(3):167-86. PubMed ID: 3042215 [TBL] [Abstract][Full Text] [Related]
2. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Jennings AM; Lewis KS; Murdoch S; Talbot JF; Bradley C; Ward JD Diabetes Care; 1991 Aug; 14(8):738-44. PubMed ID: 1954811 [TBL] [Abstract][Full Text] [Related]
3. Continuous subcutaneous insulin infusion in adults: glycemic advantage is predicted by venous plasma C-peptide concentrations. Rodger NW; Dupre J; Canny CL; Brown WF Diabetes Care; 1985; 8(5):447-55. PubMed ID: 3902423 [TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous insulin infusion treatment in insulin-dependent diabetic patients: a comparison with conventional optimized treatment in a long-term study. Calabrese G; Bueti A; Santeusanio F; Giombolini A; Zega G; Angeletti G; Cartechini MG; Brunetti P Diabetes Care; 1982; 5(5):457-65. PubMed ID: 7188333 [TBL] [Abstract][Full Text] [Related]
5. A crossover comparison of continuous insulin infusion and conventional injection treatment of type I diabetes. Helve E; Koivisto VA; Lehtonen A; Pelkonen R; Huttunen JK; Nikkilä EA Acta Med Scand; 1987; 221(4):385-93. PubMed ID: 3300175 [TBL] [Abstract][Full Text] [Related]
6. Plasma immunoreactive somatostatin response to arginine after glycemic control with continuous subcutaneous insulin infusion in type I diabetics. Kobayashi T; Sawano S; Itoh T; Kosaka K Diabetes Care; 1987; 10(3):286-92. PubMed ID: 2885161 [TBL] [Abstract][Full Text] [Related]
7. Metabolic control in newly kidney transplanted insulin-dependent diabetics: improvement by insulin pump treatment (CSII). Schmitz O; Sorensen SS; Alberti KG; Orskov H; Hansen HE J Diabet Complications; 1987; 1(3):81-6. PubMed ID: 2969910 [TBL] [Abstract][Full Text] [Related]
8. Observations on C-peptide and free insulin in the blood during continuous subcutaneous insulin infusion and conventional insulin therapy. Bergenstal RM; Dupre J; Lawson PM; Rizza RA; Rubenstein AH Diabetes; 1985 Aug; 34 Suppl 3():31-6. PubMed ID: 3926568 [TBL] [Abstract][Full Text] [Related]
9. Remission from insulin dependence induced by continuous subcutaneous insulin infusion (CSII) in type I, newly diagnosed diabetics: role of some hormonal and immunologic factors. Nardelli GM; Guastamacchia E; Di Paolo S; Lattanzi V; Ciampolillo A; Montedoro P; Giorgino R Acta Diabetol Lat; 1988; 25(4):343-50. PubMed ID: 3266701 [TBL] [Abstract][Full Text] [Related]
10. Continuous subcutaneous insulin infusion versus injection therapy: a randomized cross-over trial under usual diabetic clinic conditions. Marshall SM; Home PD; Taylor R; Alberti KG Diabet Med; 1987; 4(6):521-5. PubMed ID: 2962807 [TBL] [Abstract][Full Text] [Related]
11. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011 [TBL] [Abstract][Full Text] [Related]